0000899243-23-014886.txt : 20230608
0000899243-23-014886.hdr.sgml : 20230608
20230608163835
ACCESSION NUMBER: 0000899243-23-014886
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230608
FILED AS OF DATE: 20230608
DATE AS OF CHANGE: 20230608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sandoval Elisabeth
CENTRAL INDEX KEY: 0001632295
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39041
FILM NUMBER: 231002490
MAIL ADDRESS:
STREET 1: C/O KYTHERA BIOPHARMACEUTICALS, INC.
STREET 2: 30930 RUSSELL RANCH ROAD, 3RD FLOOR
CITY: WESTLAKE VILLAGE
STATE: CA
ZIP: 91362
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001692830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813039831
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4819 EMPEROR BOULEVARD
STREET 2: SUITE 340
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: 415-505-0809
MAIL ADDRESS:
STREET 1: 4819 EMPEROR BOULEVARD
STREET 2: SUITE 340
CITY: DURHAM
STATE: NC
ZIP: 27703
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-08
1
0001692830
Satsuma Pharmaceuticals, Inc.
STSA
0001632295
Sandoval Elisabeth
C/O SATSUMA PHARMACEUTICALS, INC.
400 OYSTER POINT BOULEVARD, SUITE 221
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
0
Stock Option (right to buy)
26.99
2023-06-08
4
D
0
10000
0.00
D
Common Stock
10000
0
D
Stock Option (right to buy)
4.60
2023-06-08
4
D
0
20000
0.00
D
Common Stock
20000
0
D
Stock Option (right to buy)
3.46
2023-06-08
4
D
0
30000
0.00
D
Common Stock
30000
0
D
Stock Option (right to buy)
4.56
2023-06-08
4
D
0
14893
0.00
D
Common Stock
14893
0
D
Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
/s/ Thomas P. O'Neil as Attorney in Fact for Elisabeth Sandoval
2023-06-08